Literature DB >> 7845688

MTS-1 (CDKN2) tumor suppressor gene deletions are a frequent event in esophagus squamous cancer and pancreatic adenocarcinoma cell lines.

Q Liu1, Y X Yan, M McClure, H Nakagawa, F Fujimura, A K Rustgi.   

Abstract

MTS-1 is a candidate tumor suppressor gene on chromosome 9p21-22, a region frequently observed to have loss of heterozygosity in esophagus squamous cell carcinomas and pancreatic ductal adenocarcinomas. In order to determine whether MTS-1 sequences are deleted or mutated in cell lines derived from these cancers, we performed PCR amplification of MTS-1 exons 1 and 2. In this fashion, we found that 67% of esophagus squamous cancer cell lines have deletions of both exons 1 and 2, and 50% of pancreatic cancer cell lines have similar deletions. Furthermore, an additional 30% of pancreatic cancer cell lines harbored point mutations or microdeletions based on DNA sequencing. MTS-1 encodes p16, an inhibitor of cyclin-dependent kinase 4 (cdk4) which complexes with cyclin D1. Our data suggest that MTS-1 deletions and mutations may play an important role in the molecular pathogenesis of esophagus squamous cell and pancreatic cancers.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7845688

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  6 in total

Review 1.  Molecular oncology in pancreatic cancer.

Authors:  S Gansauge; F Gansauge; H G Beger
Journal:  J Mol Med (Berl)       Date:  1996-06       Impact factor: 4.599

2.  p16/CDKN2 alterations and pRb expression in oesophageal squamous carcinoma.

Authors:  G Busatto; Y H Shiao; A R Parenti; R Baffa; A Ruol; M Plebani; M Rugge
Journal:  Mol Pathol       Date:  1998-04

3.  Comparative phenotypic studies of duct epithelial cell lines derived from normal human pancreas and pancreatic carcinoma.

Authors:  N Liu; T Furukawa; M Kobari; M S Tsao
Journal:  Am J Pathol       Date:  1998-07       Impact factor: 4.307

4.  Cellular senescence checkpoint function determines differential Notch1-dependent oncogenic and tumor-suppressor activities.

Authors:  S Kagawa; M Natsuizaka; K A Whelan; N Facompre; S Naganuma; S Ohashi; H Kinugasa; A M Egloff; D Basu; P A Gimotty; A J Klein-Szanto; A J Bass; K-K Wong; J A Diehl; A K Rustgi; H Nakagawa
Journal:  Oncogene       Date:  2014-06-16       Impact factor: 9.867

5.  p16/CDKN2 gene and p53 gene alterations in Japanese non-smoking female lung adenocarcinoma.

Authors:  Y Takeshima; T Nishisaka; R Kawano; K Kishizuchi; S Fujii; S Kitaguchi; K Inai
Journal:  Jpn J Cancer Res       Date:  1996-02

6.  Constitutional mutation in CDKN2A is associated with long term survivorship in multiple myeloma: a case report.

Authors:  Vallari Shah; Kevin D Boyd; Richard S Houlston; Martin F Kaiser
Journal:  BMC Cancer       Date:  2017-11-06       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.